37.27
前日終値:
$37.06
開ける:
$37
24時間の取引高:
1.98M
Relative Volume:
0.51
時価総額:
$15.70B
収益:
$2.26B
当期純損益:
$1.09B
株価収益率:
15.91
EPS:
2.3431
ネットキャッシュフロー:
$2.70B
1週間 パフォーマンス:
+3.24%
1か月 パフォーマンス:
+3.90%
6か月 パフォーマンス:
+16.65%
1年 パフォーマンス:
+29.86%
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
RPRX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RPRX
Royalty Pharma Plc
|
37.27 | 15.62B | 2.26B | 1.09B | 2.70B | 2.3431 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-16 | 開始されました | Morgan Stanley | Overweight |
2024-06-03 | ダウングレード | UBS | Buy → Neutral |
2022-06-14 | 再開されました | UBS | Buy |
2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
2022-04-27 | 開始されました | Goldman | Buy |
2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
2022-04-06 | 再開されました | Morgan Stanley | Overweight |
2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
2021-07-30 | 開始されました | Tigress Financial | Buy |
2020-11-09 | アップグレード | UBS | Neutral → Buy |
2020-07-14 | 開始されました | Evercore ISI | In-line |
2020-07-13 | 開始されました | BofA Securities | Buy |
2020-07-13 | 開始されました | Citigroup | Neutral |
2020-07-13 | 開始されました | Cowen | Outperform |
2020-07-13 | 開始されました | Goldman | Neutral |
2020-07-13 | 開始されました | JP Morgan | Neutral |
2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
2020-07-13 | 開始されました | SunTrust | Buy |
2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma plc stock volume spike explainedScalable Portfolio Growth Suggestions Released - metal.it
Published on: 2025-07-29 22:21:39 - metal.it
Machine Learning Models Forecast Royalty Pharma plc UptickConsistent Income Focused Trade List Analyzed - metal.it
Can Royalty Pharma plc Regain Momentum After BreakdownCommunity Shared Smart Money Signals Show Movement - metal.it
Bollinger Bands Expand on Royalty Pharma plc — Volatility AheadWeekly Chart Analysis With Entry Advice Provided - metal.it
Royalty Pharma stock hits 52-week high at 36.89 USD - Investing.com Australia
Why is Royalty Pharma plc stock attracting strong analyst attentionExceptional stock performance - jammulinksnews.com
Is it the right time to buy Royalty Pharma plc stockSuperior portfolio returns - jammulinksnews.com
Ridgewood Investments LLC Decreases Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What makes Royalty Pharma plc stock price move sharplyInvest confidently with real-time updates - jammulinksnews.com
Mediolanum International Funds Ltd Lowers Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Position Trimmed by Allianz Asset Management GmbH - MarketBeat
Envestnet Asset Management Inc. Boosts Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Cwm LLC Increases Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What is Royalty Pharma plc company’s growth strategyUnmatched profit growth - jammulinksnews.com
How does Royalty Pharma plc compare to its industry peersCapitalize on strong market momentum - jammulinksnews.com
Is Royalty Pharma plc stock overvalued or undervaluedUnlock powerful trading signals and alerts - jammulinksnews.com
Published on: 2025-07-28 08:51:02 - jammulinksnews.com
What are the latest earnings results for Royalty Pharma plcMaximize your portfolio’s earning potential - jammulinksnews.com
When is Royalty Pharma plc stock expected to show significant growthDynamic profit opportunities - jammulinksnews.com
What markets is GCLWW expanding into Is Royalty Pharma plc stock a good long term investment optionGet daily updates on promising stocks - jammulinksnews.com
Vestor Capital LLC Takes $12.60 Million Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month HighHere's What Happened - MarketBeat
Royalty Pharma: A High-Margin, Earnings-Driven Opportunity in the Biopharma Royalty Space - AInvest
Baillie Gifford & Co. Has $417.21 Million Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What analysts say about Royalty Pharma plc stockFree Wealth Planning Blueprint - PrintWeekIndia
Royalty Pharma plc Stock Analysis and ForecastSuperior portfolio returns - PrintWeekIndia
Is Royalty Pharma plc a good long term investmentDouble-digit growth - Autocar Professional
Royalty Pharma (NASDAQ:RPRX) Given New $42.00 Price Target at Citigroup - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Holdings Lifted by Los Angeles Capital Management LLC - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by New York State Common Retirement Fund - MarketBeat
Royalty Pharma Plc's (NASDAQ:RPRX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - 富途牛牛
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
Edgestream Partners L.P. Makes New $659,000 Investment in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What drives Royalty Pharma plc stock pricePhenomenal wealth increase - Autocar Professional
Citigroup maintains Buy rating, raises PT for Royalty Pharma to $42. - AInvest
Citi raises Royalty Pharma stock price target to $42 on CF and Tremfya growth By Investing.com - Investing.com South Africa
Citi raises Royalty Pharma stock price target to $42 on CF and Tremfya growth - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised to $42 at Citi - StreetInsider
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):